Bajaj Finance Robust FY26 Performance with Consolidated Profit at ₹19,332 Crore

Bajaj Finance Limited has announced strong financial results for the financial year ended March 31, 2026. The company achieved a consolidated profit after tax of ₹19,332 crore, reflecting significant growth. Consolidated assets under management (AUM) crossed the ₹5 lakh crore milestone, standing at ₹509,975 crore, a 22% increase year-on-year. New loans booked during the year reached 52.45 million, underscoring the company’s continued market expansion.

Annual Financial Performance Highlights

For the financial year 2025-26, Bajaj Finance reported impressive consolidated results. The company’s consolidated profit after tax (before one-time actions) stood at ₹20,689 crore, representing a growth of 24% over the previous year. The total AUM growth of 22% was driven by broad-based expansion across diverse lending portfolios, including significant growth in Gold Loans and Mortgages.

Strategic Milestones and One-Time Actions

The company achieved a major milestone by crossing 50 million new loans booked in FY26. Financial performance was shaped by strategic provisioning and presentation changes to align with evolving accounting standards. Notable one-time actions during the year included an accelerated ECL provision of ₹1,406 crore in Q3 FY26 and a one-time charge related to the implementation of new labour codes.

Subsidiary and Dividend Updates

Bajaj Housing Finance Limited reported strong performance with profit after tax of ₹2,560 crore for FY26, a 18% increase, and an AUM growth of 23%. Bajaj Financial Securities Limited also showed robust growth, with profit after tax rising to ₹203 crore. The Board of Directors has recommended a final dividend of ₹6 per equity share for the financial year ended March 31, 2026, which includes a special payout of ₹0.60 per share from the gain on the sale of housing finance subsidiary shares.

Source: BSE

Previous Article

EIH Limited Confirmation of Non-Large Corporate Status

Next Article

Piramal Pharma Limited Appointment of Key Managerial Personnel